Орнитокс

General characteristics. Structure:

Deystvuyushche substance: 500 mg of L - ornithine - L - aspartate in 1 ml of solution.

Excipients: water for ninjektion.

New effective drug in a gepatoprotektion, a detoxication and proteinaceous and carbohydrate correction, real chance of rescue at any damages of a liver.

Pharmacological properties:

Pharmacodynamics. In vivo action of L - ornithine – L - aspartate is caused by amino acids, ornithine and aspartate by means of two key methods of a detoxication of ammonia: synthesis of urea and synthesis of a glutamine.

Synthesis of urea happens in periportal hepatocytes where ornithine acts as the activator of two enzymes: ornithine karbamoit transferases and karbamoit sintetaza phosphate and also as substrate for urea synthesis.

Synthesis of a glutamine happens in navkolovenozny hepatocytes. In particular, in pathological conditions aspartate and dicarboxylat, including ornithine metabolism products, are absorbed in cells and used for binding of ammonia in the form of a glutamine there.

The glutamate is an amino acid which connects ammonia as in physiological, and pathological conditions. The received amino acid a glutamine is not only not a toxic form for ammonia removal, but also activates an important cycle of urea (intracellular exchange of a glutamine).

In physiological conditions ornithine and aspartate do not limit urea synthesis.

Pharmacokinetics. An elimination half-life of both ornithine, and aspartate short – 0,3–0,4 hours. An insignificant part of aspartate is removed with urine in not changed look.

Indications to use:

Treatment of the associated diseases and complications caused by disturbance of detoksikatsionny function of a liver (for example at cirrhosis) with symptoms of the latent or expressed hepatic encephalopathy, especially consciousness disturbances (a prekom, a lump).

Route of administration and doses:

If it is not appointed differently, to apply up to 4 ampoules (40 ml) a day.

In case of a prekoma or a coma to enter to 8 ampoules (80 ml) within 24 hours, depending on weight of a state.

Before introduction to add contents of ampoules to 500 ml of infusion solution, but it is not necessary to dissolve more than 6 ampoules in 500 ml of infusion solution.

The maximum rate of administering of L - ornithine – L - aspartate makes 5 g/h (corresponds to contents of 1 ampoule).

The course of treatment is defined by the doctor depending on a condition of the patient.

Dose adjustment for patients of advanced age is not required.

Features of use:

Use during pregnancy or feeding by a breast. There is no sufficient experience of use of drug therefore during pregnancy drug should be used only according to vital indications when the expected advantage for mother exceeds possible risk for a fruit. During treatment it is necessary to stop feeding by a breast.

Children. Experience of use to children is absent.

As introduction of high doses of drug can cause increase in level of uric acid in a blood plasma, it is necessary to control urea level in a blood plasma.

Ability to influence speed of response at control of motor transport or work with other mechanisms. Due to an opportunity dizziness, it is necessary to avoid control of motor transport or work with other mechanisms during treatment.

Side effects:

Gastrointestinal frustration: nausea, diarrhea, abdominal pain, lock, vomiting, meteorism.

Neurologic frustration: dizziness.

Disturbances from immune system: hypersensitivity reactions, including a Quincke's disease, an acute anaphylaxis, sneezing, dacryagogue.

From skin and hypodermic cellulose: skin rashes, itch, urticaria.

From muscular system: muscle pains are possible (are temporary, pass independently, do not demand drug withdrawal).

Metabolic frustration: at use in high doses increase in level of uric acid in a blood plasma is possible.

At emergence of complaints to nausea, dizziness it is necessary to reduce Ornitoks rate of administering.

Others: changes in an injection site, erubescence.

Interaction with other medicines:

Are not revealed.

Contraindications:

Hypersensitivity to drug components.

The expressed renal failure (the clearance of creatinine is higher than 3 mg / 100 ml).

Overdose:

In case of overdose increase in level of urea in blood and urine, strengthening of manifestations of side reactions can be observed.

Treatment. The specific antidote is unknown. Symptomatic treatment.

Storage conditions:

To store at a temperature not over 25 ºС in original packaging and the place, unavailable to children! Not to freeze. Period of validity 3 years.

Issue conditions:

According to the recipe

Packaging:

5 ampoules on 10 ml of solution soldered in the plastic pallet. On 1 plastic pallet in a cardboard pack together with the application instruction.